Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.

Kalra M, Gerdemann U, Luu JD, Ngo MC, Leen AM, Louis CU, Rooney CM, Gottschalk S.

Cytotherapy. 2019 Feb;21(2):212-223. doi: 10.1016/j.jcyt.2018.08.001. Epub 2018 Nov 2.

PMID:
30396848
2.

Targeted reconstruction of T cell receptor sequence from single cell RNA-seq links CDR3 length to T cell differentiation state.

Afik S, Yates KB, Bi K, Darko S, Godec J, Gerdemann U, Swadling L, Douek DC, Klenerman P, Barnes EJ, Sharpe AH, Haining WN, Yosef N.

Nucleic Acids Res. 2017 Sep 19;45(16):e148. doi: 10.1093/nar/gkx615.

3.

The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.

Wang H, Nicolay BN, Chick JM, Gao X, Geng Y, Ren H, Gao H, Yang G, Williams JA, Suski JM, Keibler MA, Sicinska E, Gerdemann U, Haining WN, Roberts TM, Polyak K, Gygi SP, Dyson NJ, Sicinski P.

Nature. 2017 Jun 15;546(7658):426-430. doi: 10.1038/nature22797. Epub 2017 Jun 7.

4.

The epigenetic landscape of T cell exhaustion.

Sen DR, Kaminski J, Barnitz RA, Kurachi M, Gerdemann U, Yates KB, Tsao HW, Godec J, LaFleur MW, Brown FD, Tonnerre P, Chung RT, Tully DC, Allen TM, Frahm N, Lauer GM, Wherry EJ, Yosef N, Haining WN.

Science. 2016 Dec 2;354(6316):1165-1169. Epub 2016 Oct 27.

5.

Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.

Papadopoulou A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C, Leung K, Carrum G, Gee AP, Vera JF, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM.

Sci Transl Med. 2014 Jun 25;6(242):242ra83. doi: 10.1126/scitranslmed.3008825.

6.

Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.

Weber G, Caruana I, Rouce RH, Barrett AJ, Gerdemann U, Leen AM, Rabin KR, Bollard CM.

Clin Cancer Res. 2013 Sep 15;19(18):5079-91. doi: 10.1158/1078-0432.CCR-13-0955. Epub 2013 Jul 9.

7.

Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.

Gerdemann U, Katari UL, Papadopoulou A, Keirnan JM, Craddock JA, Liu H, Martinez CA, Kennedy-Nasser A, Leung KS, Gottschalk SM, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM.

Mol Ther. 2013 Nov;21(11):2113-21. doi: 10.1038/mt.2013.151. Epub 2013 Jun 20.

8.

Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.

Weber G, Gerdemann U, Caruana I, Savoldo B, Hensel NF, Rabin KR, Shpall EJ, Melenhorst JJ, Leen AM, Barrett AJ, Bollard CM.

Leukemia. 2013 Jul;27(7):1538-47. doi: 10.1038/leu.2013.66. Epub 2013 Mar 1.

9.

Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.

Ramos CA, Narala N, Vyas GM, Leen AM, Gerdemann U, Sturgis EM, Anderson ML, Savoldo B, Heslop HE, Brenner MK, Rooney CM.

J Immunother. 2013 Jan;36(1):66-76. doi: 10.1097/CJI.0b013e318279652e.

10.

Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation.

Gerdemann U, Keukens L, Keirnan JM, Katari UL, Nguyen CT, de Pagter AP, Ramos CA, Kennedy-Nasser A, Gottschalk SM, Heslop HE, Brenner MK, Rooney CM, Leen AM.

Blood. 2013 Jan 3;121(1):207-18. doi: 10.1182/blood-2012-05-430413. Epub 2012 Nov 14.

11.

Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.

Gerdemann U, Keirnan JM, Katari UL, Yanagisawa R, Christin AS, Huye LE, Perna SK, Ennamuri S, Gottschalk S, Brenner MK, Heslop HE, Rooney CM, Leen AM.

Mol Ther. 2012 Aug;20(8):1622-32. doi: 10.1038/mt.2012.130. Epub 2012 Jul 17.

12.

The transcription factor Lyl-1 regulates lymphoid specification and the maintenance of early T lineage progenitors.

Zohren F, Souroullas GP, Luo M, Gerdemann U, Imperato MR, Wilson NK, Göttgens B, Lukov GL, Goodell MA.

Nat Immunol. 2012 Jul 8;13(8):761-9. doi: 10.1038/ni.2365.

13.

Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients.

Pesonen S, Diaconu I, Kangasniemi L, Ranki T, Kanerva A, Pesonen SK, Gerdemann U, Leen AM, Kairemo K, Oksanen M, Haavisto E, Holm SL, Karioja-Kallio A, Kauppinen S, Partanen KP, Laasonen L, Joensuu T, Alanko T, Cerullo V, Hemminki A.

Cancer Res. 2012 Apr 1;72(7):1621-31. doi: 10.1158/0008-5472.CAN-11-3001. Epub 2012 Feb 9.

14.

Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.

Gerdemann U, Katari U, Christin AS, Cruz CR, Tripic T, Rousseau A, Gottschalk SM, Savoldo B, Vera JF, Heslop HE, Brenner MK, Bollard CM, Rooney CM, Leen AM.

Mol Ther. 2011 Dec;19(12):2258-68. doi: 10.1038/mt.2011.167. Epub 2011 Sep 13.

15.

Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.

Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, Horton TM, Sheehan A, Copeland A, Younes A, Rooney CM, Heslop HE, Bollard CM.

Clin Cancer Res. 2011 Nov 15;17(22):7058-66. doi: 10.1158/1078-0432.CCR-11-1873. Epub 2011 Sep 9. Erratum in: Clin Cancer Res. 2012 Feb 1;18(3):913. Dosage error in article text.

16.

Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant.

Gerdemann U, Vera JF, Rooney CM, Leen AM.

J Vis Exp. 2011 May 27;(51). pii: 2736. doi: 10.3791/2736.

17.

Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers.

Luke JM, Vincent JM, Du SX, Gerdemann U, Leen AM, Whalen RG, Hodgson CP, Williams JA.

Gene Ther. 2011 Apr;18(4):334-43. doi: 10.1038/gt.2010.149. Epub 2010 Nov 25.

PMID:
21107439
18.

Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).

Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H, Wilson J, Dotti G, Heslop HE, Leen AM, Rooney CM.

J Immunother. 2010 Apr;33(3):305-15. doi: 10.1097/CJI.0b013e3181c0c3cb.

19.

Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.

Gerdemann U, Christin AS, Vera JF, Ramos CA, Fujita Y, Liu H, Dilloo D, Heslop HE, Brenner MK, Rooney CM, Leen AM.

Mol Ther. 2009 Sep;17(9):1616-25. doi: 10.1038/mt.2009.140. Epub 2009 Jul 7.

20.

Up-regulation of c-FLIPS+R upon CD40 stimulation is associated with inhibition of CD95-induced apoptosis in primary precursor B-ALL.

Troeger A, Schmitz I, Siepermann M, Glouchkova L, Gerdemann U, Janka-Schaub GE, Schulze-Osthoff K, Dilloo D.

Blood. 2007 Jul 1;110(1):384-7. Epub 2007 Mar 21.

PMID:
17376892
21.

[Differentiation of peripheral and central hyperalgesic effects of systemic procaine].

Gerdemann U, Brückl V, Nassr NA, Märkert D, Sittl R, Koppert W.

Schmerz. 2004 Jun;18(3):189-96. German.

PMID:
15206017
22.

Attenuated Yersinia pseudotuberculosis carrier vaccine for simultaneous antigen-specific CD4 and CD8 T-cell induction.

Rüssmann H, Gerdemann U, Igwe EI, Panthel K, Heesemann J, Garbom S, Wolf-Watz H, Geginat G.

Infect Immun. 2003 Jun;71(6):3463-72.

Supplemental Content

Loading ...
Support Center